{
  "data": {
    "asOf": "2026-10-30T22:27:41.224Z",
    "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
    "byRegistry": {
      "isrctn": 1
    },
    "canonicalTrial": {
      "canonicalId": "ISRCTN39379437",
      "title": "A study of guselkumab versus risankizumab in participants with moderately to severely active Crohn's Disease",
      "scientificTitle": "A phase 3b, multicenter, randomized, open-label, active-controlled study to compare the efficacy and safety of guselkumab versus risankizumab in the treatment of participants with moderately to severely active Crohn’s Disease",
      "status": "recruiting",
      "studyType": "interventional",
      "phase": [],
      "conditions": [
        "Moderately to severely active Crohn's Disease"
      ],
      "interventions": [
        {
          "type": "Drug",
          "description": "Experimental: Guselkumab\nParticipants will receive guselkumab induction dose subcutaneously (SC) at Weeks 0, 4, and 8 followed by guselkumab maintenance dose SC once every 4 weeks (q4w) from Week 12 through Week 52.\n\nExperimental: Risankizumab\nParticipants will receive risankizumab induction dose intravenously (IV) at Weeks 0, 4, and 8 followed by risankizumab maintenance dose SC once every 8 weeks (q8w) from Week 12 through Week 52."
        }
      ],
      "sponsor": null,
      "locations": [
        {
          "country": "United Kingdom"
        },
        {
          "country": "Austria"
        },
        {
          "country": "Belgium"
        },
        {
          "country": "Canada"
        },
        {
          "country": "China"
        },
        {
          "country": "Czech Republic"
        },
        {
          "country": "Denmark"
        },
        {
          "country": "France"
        },
        {
          "country": "Germany"
        },
        {
          "country": "Hungary"
        },
        {
          "country": "Italy"
        },
        {
          "country": "Netherlands"
        },
        {
          "country": "Poland"
        },
        {
          "country": "Slovakia"
        },
        {
          "country": "Spain"
        },
        {
          "country": "Sweden"
        }
      ],
      "outcomes": {
        "other": [],
        "primary": [],
        "secondary": []
      },
      "eligibility": {
        "gender": "All",
        "exclusion": "1. Has complications of CD such as symptomatic strictures or stenoses, short gut syndrome, active draining stoma or significant fistulizing disease or any other manifestation anticipated to require surgery within the next year, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab or risankizumab\n2. Currently has or is suspected to have an abscess\n3. Has an active fistula during screening or at Week 0 with an anticipated need for surgery\n4. Has had any kind of bowel resection within 24 weeks, or any other intraabdominal or other major surgery within 12 weeks, before first dose of study intervention\n5. Currently has a malignancy or has a history of malignancy within 5 years before screening",
        "inclusion": "1. Has CD or fistulizing Crohn's Disease (CD) of at least 12 weeks’ duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and/or endoscopy\n2. Have moderately to severely active CD, defined as baseline Crohn’s Disease Activity Index (CDAI) score greater than or equal to (>=) 220 but less than or equal to (<=) 450\n3. Baseline endoscopic evidence of active ileal and/or colonic CD as assessed by central endoscopy reading at the screening endoscopy defined as a screening Simple Endoscopic Score for Crohn’s Disease (SES CD) >= 4 (for participants with isolated ileal disease) or >= 6 (for participants with colonic or ileocolonic disease), based on the presence of ulceration in any 1 of the 5 ileocolonic segments, resulting in the following specified ulceration component scores:\na. A minimum score of 1 for the component of “size of ulcers” AND\nb. A minimum score of 1 for the component of “ulcerated surface\"\n4. In the opinion of the investigator, participant’s disease is appropriate to treat with the maintenance dosing regimens utilized in the study\n5. Adhere to the requirements for concomitant medications for the treatment of CD as mentioned in the protocol",
        "lowerAgeLimit": null,
        "upperAgeLimit": null,
        "healthyVolunteersAllowed": "false"
      },
      "enrollment": {
        "final": "0",
        "target": "530"
      },
      "startDate": "2026-04-19",
      "completionDate": "2030-12-11",
      "lastUpdated": "2026-10-26T16:25:20.260Z",
      "firstPosted": "2026-03-26T06:51:43.413Z",
      "resultsAvailable": false,
      "sourceRegistries": [
        "isrctn"
      ],
      "sourceUrls": [
        "https://www.isrctn.com/ISRCTN39379437"
      ]
    },
    "identifiers": [
      {
        "idType": "eudract",
        "idValue": "2025-521590-13",
        "declaredBy": "isrctn"
      },
      {
        "idType": "isrctn",
        "idValue": "ISRCTN39379437",
        "declaredBy": "isrctn"
      }
    ],
    "sourceRecords": [
      {
        "registry": "isrctn",
        "registryName": "ISRCTN",
        "license": "public",
        "sourceId": "ISRCTN39379437",
        "sourceUrl": "https://www.isrctn.com/ISRCTN39379437",
        "sourceStatus": "recruitmentStart=2026-04-19T00:00:00.000Z;recruitmentEnd=2027-11-16T00:00:00.000Z;overallEnd=2030-12-11T00:00:00.000Z",
        "retrievedAt": "2026-10-28T04:34:44.126Z",
        "payloadSha256": "e3ec9f7299db76bd4107591132f399be259955247326afebfbef5d58263e0c94",
        "piiRedacted": true
      }
    ],
    "citation": {
      "canonicalId": "ISRCTN39379437",
      "sources": [
        {
          "registry": "isrctn",
          "registryName": "ISRCTN",
          "license": "public",
          "sourceId": "ISRCTN39379437",
          "verifyAt": "https://www.isrctn.com/ISRCTN39379437",
          "retrievedAt": "2026-10-28T04:34:44.126Z",
          "payloadSha256": "e3ec9f7299db76bd4107591132f399be259955247326afebfbef5d58263e0c94",
          "text": "ISRCTN, record ISRCTN39379437 (https://www.isrctn.com/ISRCTN39379437), retrieved 2026-10-28, licence: public."
        }
      ],
      "crossRegistry": false,
      "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
      "text": "Trial ISRCTN39379437, registered in ISRCTN, retrieved 2026-10-28. Verify at the source URLs listed; each retrieval is checksummed.",
      "note": "Only one registry is known to hold this trial. Absence from the others is not evidence it was not registered there."
    },
    "provenanceNote": "Personal contact fields (names, emails, phone numbers, addresses) are stripped from every stored payload. No participant-level data is collected or served."
  },
  "_meta": {
    "api": "The Last Economy Wire: World Trials API",
    "version": "1.0",
    "schemaVersion": "1",
    "correlationId": "req_LhMck2D8zOWA",
    "generatedAt": "2026-10-30T22:27:41.224Z",
    "documentation": "https://negativeresistance.com/embed",
    "license": "Free for any use. Attribution appreciated.",
    "degraded": false,
    "provenance": {
      "sources": [
        "isrctn"
      ],
      "attribution": {
        "isrctn": "ISRCTN: licence: public, https://www.isrctn.com/"
      },
      "dedupMethod": "exact cross-registry identifier matching; probabilistic = review only",
      "limitations": [
        {
          "source": "isrctn",
          "issue": "Fields not reliably populated: phase, outcomes, resultsAvailable."
        }
      ],
      "provenanceEndpoint": "/api/v1/sources"
    },
    "freshness": {
      "newestEvidenceAt": null,
      "lastSyncedAt": {
        "isrctn": "2026-10-28T04:35:25.254Z"
      },
      "degradedSources": [],
      "worldwide": false,
      "maxAgeHours": 65.9,
      "fromCache": false
    },
    "links": {
      "discovery": "https://negativeresistance.com/api/v1",
      "openapi": "https://negativeresistance.com/api/v1/openapi.json",
      "mcp": "https://negativeresistance.com/api/v1/mcp",
      "agentCard": "https://negativeresistance.com/.well-known/agent.json",
      "aiPlugin": "https://negativeresistance.com/.well-known/ai-plugin.json",
      "sdk": "https://negativeresistance.com/api/v1/sdk",
      "status": "https://negativeresistance.com/api/v1/status",
      "provenance": "https://negativeresistance.com/api/v1/sources",
      "contract": "https://negativeresistance.com/api/v1/contract",
      "curriculum": "https://negativeresistance.com/api/v1/curriculum",
      "graph": "https://negativeresistance.com/api/v1/graph",
      "openQuestions": "https://negativeresistance.com/api/v1/open-questions",
      "scoreboard": "https://negativeresistance.com/api/v1/scoreboard",
      "findings": "https://negativeresistance.com/api/v1/findings",
      "claims": "https://negativeresistance.com/api/v1/claims",
      "threads": "https://negativeresistance.com/api/v1/threads",
      "assignment": "https://negativeresistance.com/api/v1/assignment",
      "changes": "https://negativeresistance.com/api/v1/changes",
      "hello": "https://negativeresistance.com/api/v1/hello",
      "errors": "https://negativeresistance.com/api/v1/errors",
      "webhooks": "https://negativeresistance.com/api/v1/webhooks",
      "a2a": "https://negativeresistance.com/api/v1/a2a",
      "deadEnds": "https://negativeresistance.com/api/v1/dead-ends",
      "decompositions": "https://negativeresistance.com/api/v1/decompositions",
      "rungs": "https://negativeresistance.com/api/v1/rungs",
      "methods": "https://negativeresistance.com/api/v1/methods",
      "reality": "https://negativeresistance.com/api/v1/reality",
      "council": "https://negativeresistance.com/api/v1/council",
      "calibration": "https://negativeresistance.com/api/v1/calibration",
      "freshness": "https://negativeresistance.com/api/v1/freshness",
      "mission": "https://negativeresistance.com/api/v1/mission",
      "twin": "https://negativeresistance.com/api/v1/twin",
      "twinExperiment": "https://negativeresistance.com/api/v1/twin/experiment",
      "betaCell": "https://negativeresistance.com/api/v1/twin/beta-cell",
      "patientModel": "https://negativeresistance.com/api/v1/twin/patient-model",
      "agentCardCanonical": "https://negativeresistance.com/.well-known/agent-card.json",
      "collaborate": "https://negativeresistance.com/collaborate",
      "manifesto": "https://negativeresistance.com/about",
      "documentation": "https://negativeresistance.com/embed",
      "connect": "https://negativeresistance.com/connect",
      "llmsTxt": "https://negativeresistance.com/llms.txt",
      "llmsFullTxt": "https://negativeresistance.com/llms-full.txt"
    },
    "disclaimer": "Research data from public registries and literature; not medical advice."
  }
}